Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ARVN
- Price
- 7.29
- Stock movement up
- +0.59 (8.89%)
- Company name
- Arvinas Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 500.57M
- Ent value
- 996.47M
- Price/Sales
- 3.11
- Price/Book
- 0.85
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.50%
- 1 year return
- -79.32%
- 3 year return
- -45.35%
- 5 year return
- -30.21%
- 10 year return
- -
Last updated: 2025-05-29
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ARVN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.11 |
| Price to Book | 0.85 |
| EV to Sales | 6.19 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 68.71M |
| EPS (TTM) | -4.28 |
| FCF per share (TTM) | -3.60 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 161.10M |
| Gross profit (TTM) | 156.00M |
| Operating income (TTM) | -357.40M |
| Net income (TTM) | -308.60M |
| EPS (TTM) | -4.28 |
| EPS (1y forward) | -4.72 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 96.83% |
| Operating margin (TTM) | -221.85% |
| Profit margin (TTM) | -191.56% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 85.20M |
| Net receivables | 14.80M |
| Total current assets | 1.15B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 32.30M |
| Total assets | 1.17B |
| Accounts payable | 17.70M |
| Short/Current long term debt | 1.50M |
| Total current liabilities | 275.90M |
| Total liabilities | 581.10M |
| Shareholder's equity | 586.00M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -258.30M |
| Capital expenditures (TTM) | 1.60M |
| Free cash flow (TTM) | -259.90M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -52.66% |
| Return on Assets | -26.44% |
| Return on Invested Capital | -52.47% |
| Cash Return on Invested Capital | -44.19% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.70 |
| Daily high | 7.50 |
| Daily low | 6.70 |
| Daily Volume | 3.94M |
| All-time high | 107.87 |
| 1y analyst estimate | 63.25 |
| Beta | 1.97 |
| EPS (TTM) | -4.28 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 28 Jul 2025 |
Downside potential
Loading...
Downside potential data
| ARVN | S&P500 | |
| Current price drop from All-time high | -93.25% | -4.11% |
| Highest price drop | -94.37% | -56.47% |
| Date of highest drop | 14 May 2025 | 9 Mar 2009 |
| Avg drop from high | -45.31% | -11.06% |
| Avg time to new high | 30 days | 12 days |
| Max time to new high | 962 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
500.57M
Marketcap category
Small-cap
Description
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Employees
445
Website
Investor relations
-
SEC filings
CEO
John G. Houston
Country
USA
City
New Haven
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page